Federal Budget

What’s in the 2022-23 Federal Budget for the eye health sector?

The Federal Government has laid out a $132 billion health agenda for the coming year – if it regains power at the next election – and while there were no major wins for eye health, changes to the PBS safety net and small business incentives are expected to trickle down to the ophthalmic sector.
Read More

Beovu AMD therapy now listed on the PBS

Almost 13,000 Australians could save thousands annually with the Pharmaceutical Benefits Scheme (PBS) listing of Beovu (brolucizumab) for neovascular age-related macular degeneration (nAMD) from this month, the Federal Government says.
Read More
Novartis ophthalmology sale

Novartis secures PBS recommendation for Beovu

An independent expert panel has recommended Novartis’ treatment Beovu be subsidised through the Pharmaceutical Benefits Scheme (PBS) for neovascular age-related macular degeneration (nAMD) patients as a second-line anti-VEGF treatment.
Read More

Anti-VEGF becomes most expensive drug on PBS

The Australian government spent more than $610 million on anti-VEGF treatments during the past year, with aflibercept (Eylea) leapfrogging a hepatitis C drug to become the costliest subsidised drug for the first time.  
Read More

Dry eye treatment in Australia

Dry eye remains a very common presentation to primary eyecare practitioners in Australia. Many experienced practitioners feel that the incidence of dry eye is increasing significantly. This is a complex and multifactorial disease which begs the question: Are we doing enough for our patients and how could we do better?
Read More